Coty Up Nearly 17%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Dow Jones2026/11/05 15:58Coty Inc. Class A (COTY) is currently at $4.06, up $0.59 or 16.86%
--Would be highest close since Oct. 27, 2025, when it closed at $4.10
--On pace for largest percent increase since Nov. 19, 2020, when it rose 17.92%
--Currently up four of the past five days
--Currently up two consecutive days; up 23.25% over this period
--Best two day stretch since the two days ending Nov. 24, 2020, when it rose 24.79%
--Up 31.66% year-to-date; on pace for best year since 2023, when it rose 45.09%
--Down 87.59% from its all-time closing high of $32.68 on July 1, 2015
--Up 9.01% from 52 weeks ago (Nov. 6, 2025), when it closed at $3.72
--Would be a new 52-week closing high
--Up 119.19% from its 52-week closing low of $1.85 on June 4, 2026
--Traded as high as $4.08; highest intraday level since Nov. 6, 2025, when it hit $4.16
--Up 17.53% at today's intraday high; largest intraday percent increase since Aug. 26, 2021, when it rose as much as 20.9%
All data as of 10:56:18 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 05, 2026 10:58 ET (15:58 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
